肿瘤干/祖细胞的多药耐药机制研究进展  

Multidrug Resistance of Tumor/Progenitor Stem Cells——Review

作　　者：王磊[1] 陈宝安[1] 

机构地区：[1]东南大学医学院附属中大医院血液科,江苏南京210009

出　　处：《中国实验血液学杂志》2010年第6期1644-1648,共5页Journal of Experimental Hematology

摘　　要：肿瘤干/祖细胞是一群未/低分化、具有自我更新和分化潜能、对肿瘤的发生、发展、复发和转移起决定作用的细胞。肿瘤干/祖细胞理论的提出为肿瘤起源和本质的研究提供了新的方向和视角。对肿瘤干/祖细胞起源及多药耐药机制的研究必定会为肿瘤的治疗提供新的途径。本文就近年来肿瘤干/祖细胞的起源及多药耐药机制方面的研究进展进行综述。Tumor Stem/Progenitor Cells are characterized by undifferentiation/hypodifferention, self-renewal, differentiation potential, which is responsible for tumor occurrence, growth and metastasis. The theory about tumor stem/progenitor cells provides a new insight to recognize the origin and essence of tumors. Gaining a better insight into the origin of tumor stem/progenitor cells and the mechanisms of tumor stem/progenitor cells resistance to chemotherapy may lead to new therapeutic targets and better anticancer strategies. This review summarizes recent progress of research on the origin of tumor stem/progenitor cells and multidrug resistance.

关 键 词：肿瘤干/祖细胞 多药耐药 肿瘤发生 

分 类 号：R730.5[医药卫生—肿瘤] R730.231[医药卫生—临床医学]